Stoke Therapeutics Announces Proposed Public Offering

Share

BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 18, 2020-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way
to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced a proposed underwritten public
offering in which it intends to offer and sell, subject to market and other conditions, up to 2,500,000 shares of its common stock. In addition, Stoke
intends to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock. All of the shares of common stock
are being offered by Stoke. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC are acting as joint book-running managers in the
offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. are acting as passive bookrunners in the offering.
Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and
process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next
target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and
other general corporate purposes.
The shares are being offered by Stoke pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and
Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the
SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained
from: J.P. Morgan Securities LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New
York 11717, or by telephone: (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; from Cowen and Company, LLC c/o Broadridge
Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (833) 297-2926, or by
emailing PostSaleManualRequests@broadridge.com; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis
Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com. Electronic copies of the
preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.


About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by
precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to
target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that
fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are
called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.


Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,”
“expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include,
among others, statements the Company makes regarding its intention to conduct an offering and sale of securities, the grant of the option to purchase
additional shares, the ability to complete the offering and expected use of proceeds, Stoke’s plan to develop its precision medicine platform,
anticipated preclinical and clinical development activities, potential benefits of Stoke’s product candidates and potential market opportunities for
Stoke’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
Although Stoke believes that the expectations reflected in such forward-looking statements are reasonable, Stoke cannot guarantee future events,
results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory
approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or
results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the impact of the
COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, market conditions, the satisfaction of
customary closing conditions related to the proposed offering, as well as other risks and uncertainties described under the heading “Risk Factors” in
documents Stoke files from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Stoke specifically
disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information,
future events or otherwise, except as required by law.

Stoke Media & Investor Contact:
Dawn Kalmar
Vice President, Head of Corporate Affairs
dkalmar@stoketherapeutics.com
781-303-8302
Source: Stoke Therapeutics, Inc.